CASI Pharmaceuticals: CTOS 2015 (CASI Pharmaceuticals) - Nov 21, 2015 - “ENMD-2076 has shown clinical activity in pts with advanced STS, with clinical benefits and side effects profile typical of this class of agent”; “Drug toxicities were of low grade and tolerable. High grade toxicities include hypertension (56%), ALT increase (35%) and diarrhea (17%)”; “All 4 patients who derived clinical benefit (2 PR and 2 SD > 6months) received ENMD-2076 in the first-line setting”; “Genetic variations in CCL11 and FLNB (FilaminB) are potentially associated with benefit from ENMD-2076 while gene variations in EGFR, and CYP4B1 polymorphism could be associated with lack of benefit. These findings warrant further investigation”
P2 data • Oncology • Sarcoma
|